Newsroom

Sorted by: Latest

-

Ecolab Closes Acquisition of Ovivo's Electronics Ultrapure Water Business

ST. PAUL, Minn.--(BUSINESS WIRE)--Ecolab Inc. has closed on its previously announced acquisition of Ovivo's electronics ultrapure water business....
-

GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which GoodRx will discuss business updates. A live webcast will be available on the Compan...
-

Apogee Enterprises Announces Date for Fiscal 2026 Third Quarter Results

MINNEAPOLIS--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG) a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, today announced the company will report its fiscal 2026 third quarter results on Wednesday, January 7, 2026, before the market opens. The Company will also host a conference call at 8:00 a.m. Central Time that day. Access to the live webcast will be available at https://www.apog.c...
-

Penguin Solutions Announces First Quarter Fiscal 2026 Conference Call

FREMONT, Calif.--(BUSINESS WIRE)--Penguin Solutions will host its quarterly financial webcast & conf call for Q1FY26 earnings after market close on Tues Jan 6 at 1:30 pm PT/4:30 pm ET...
-

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand. Per the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment...
-

CRH Acquires New Jersey Business North American Aggregates

ATLANTA--(BUSINESS WIRE)--CRH today announced the acquisition of North American Aggregates (“NAA”), a leading supplier of aggregates headquartered in Perth Amboy, NJ. This strategic acquisition further expands CRH Americas Materials' aggregates business in New York and New Jersey and enhances the company’s ability to meet the long-term supply needs of customers in the region. NAA’s plant on the New Jersey waterfront brings valuable new aggregate reserves to the Tilcon NY operations along with e...
-

CareTrust REIT Announces Quarterly Dividend of $0.335 per Share

DANA POINT, Calif.--(BUSINESS WIRE)--CareTrust REIT Announces Quarterly Dividend of $0.335 per Share...
-

KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development,...
-

Accenture and Palantir Expand Global Strategic Partnership to Drive AI Reinvention

NEW YORK--(BUSINESS WIRE)--Accenture and Palantir Technologies Inc. have formed the Accenture Palantir Business Group....
-

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on December 15, 2025, it granted stock options to purchase an aggregate of 131,280 shares of common stock to el...